13087-18-8

Basic information

• Product Name: 2,2',4-Trihydroxy-Benzophenone
• Synonyms: 2,2',4-Trihydroxy-Benzophenone;(2,4-Dihydroxyphenyl)(2-hydroxyphenyl)Methanone
• CAS NO: 13087-18-8
• Molecular Formula: C₁₃H₁₀O₄
• Molecular Weight: 230.2161
• Mol File: 13087-18-8.mol
• Article Data: 10

Chemical Properties

• Melting Point: 128 °C
• Boiling Point: 424.6±20.0 °C(Predicted)
• Appearance: /
• Density: 1.413±0.06 g/cm3(Predicted)
• PKA: 7.27±0.35(Predicted)
• CAS DataBase Reference: 2,2',4-Trihydroxy-Benzophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2',4-Trihydroxy-Benzophenone(13087-18-8)
• EPA Substance Registry System: 2,2',4-Trihydroxy-Benzophenone(13087-18-8)

Safety Data

• Hazardous Substances Data: 13087-18-8(Hazardous Substances Data)

Usage

Preparation

Preparation by diazotization of 4,4′ -diamino- 2,2′ -di-hydroxybenzophenone, followed by treatment of the diazonium salt formed with 50% hypophosphorous acid (26%).

Upstream product

• 69-72-7 salicylic acid 
• 108-46-3 recorcinol 
• 118-61-6 2-hydroxy-benzoic acid ethyl ester 
• 151-10-0 1,3-Dimethoxybenzene 
• 131-53-3 (2-hydroxy-4-methoxyphenyl)(2-hydroxyphenyl)-methanone 
• 21615-34-9 2-Methoxybenzoyl chloride 
• 89-86-1 4-hydroxysalicylic acid 
• 108-95-2 phenol 
• 33077-87-1 2,2',4-trimethoxybenzophenone 

Downstream Products

• 131-53-3 (2-hydroxy-4-methoxyphenyl)(2-hydroxyphenyl)-methanone 
• 1373220-66-6 C₂₆H₂₂ClNO₃ 
• 1373220-65-5 C₂₆H₂₂FNO₃ 
• 1373220-64-4 C₂₆H₂₃NO₃ 
• 1373220-61-1 4-(allyl(4-chlorobenzyl)amino)-3-(allyloxy)-9H-xanthen-9-one 
• 1373220-60-0 4-(allyl(4-fluorobenzyl)amino)-3-(allyloxy)-9H-xanthen-9-one 
• 1373220-59-7 4-(allyl(benzyl)amino)-3-(allyloxy)-9H-xanthen-9-one 
• 109556-89-0 2,4,2'-triacetoxy-benzophenone 
• 3722-51-8 3-hydroxyxanthen-9-one 

Relevant articles and documents

Dioxybenzone triggers enhanced estrogenic effect via metabolic activation: in silico, in vitro and in vivo investigation

Dioxybenzone is widely used in cosmetics and personal care products and frequently detected in multiple environmental media and human samples. However, the current understanding of the metabolic susceptibility of dioxybenzone and the potential endocrine disruption through its metabolites in mimicking human estrogens remains largely unclear. Here we investigated the in vitro metabolism of dioxybenzone, detected the residue of metabolites in rats, and determined the estrogenic disrupting effects of these metabolites toward estrogen receptor α (ERα). In vitro metabolism revealed two major metabolites from dioxybenzone, i.e., M1 through the demethylation of methoxy moiety and M2 through hydroxylation of aromatic carbon. M1 and M2 were both rapidly detected in rat plasma upon exposure to dioxybenzone, which were then distributed into organs of rats in the order of livers > kidneys > uteri > ovaries. The 100 ns molecular dynamics simulation revealed that M1 and M2 formed hydrogen bond to residue Leu387 and Glu353, respectively, on ERα ligand binding domain, leading to a reduced binding free energy. M1 and M2 also significantly induced estrogenic effect in comparison to dioxybenzone as validated by the recombinant ERα yeast two-hybrid assay and uterotrophic assay. Overall, our study revealed the potential of metabolic activation of dioxybenzone to induce estrogenic disrupting effects, suggesting the need for incorporating metabolic evaluation into the health risk assessment of benzophenones and their structurally similar analogs. Dioxybenzone was metabolized into two major metabolites via hydroxylation and demethylation, which exhibited higher binding affinity and agonistic activity toward ERα than dioxybenzone.

ULTRAVIOLET LIGHT ABSORBERS

The present invention relates to compounds that have ultraviolet light absorbing properties, and which can also have mesogenic properties. The present invention also relates to compositions that include one or more such compounds, and to articles of manufacture that include one or more such compounds, such as optical elements that include an optical substrate and a layer that includes at least one compound of the present invention.

Synthesis, SAR and biological evaluation of natural and non-natural hydroxylated and prenylated xanthones as antitumor agents

In order to explore the detailed structure-activity relationship (SAR) around xanthone scaffold bearing hydroxyl and prenyl moieties, twenty-nine natural and non-natural hydroxylated and prenylated xanthones have been synthesized and evaluated for their in vitro anti-proliferative activities against five human cancer cell lines, including HepG2 (hepatocelluar carcinoma), HCT-116 (colon carcinoma), A549 (lung carcinoma), BGC823 (gastric carcinoma) and MDAMB- 231 (breast carcinoma). The SAR analysis revealed that the anti-proliferative activity of the xanthones is substantially influenced by the position and number of attached hydroxyl and prenyl groups, and the presence of hydroxyl group ortho to the carbonyl function of xanthone scaffold contributes significantly to their cytotoxicity. The new prenylated xanthone 20 with a relatively simple structure, namely 1,3,8-trihydroxy-2-prenylxanthone, was found to exhibit potent antitumor activities comparable to mangostin against all the five cancer cell lines. Further mechanistic studies suggested that compound 20 induces apoptosis and causes cell cycle arrest at S phase in HepG2 cells. These results have highlighted compound 20 as a new potential lead candidate for future development of novel potent broad-spectrum antitumor agents.